Biomaxima
BioMaxima S.A. produces and distributes microbiological media, reagents, and in vitro diagnostic equipment in Poland. It offers microbiology products, including ready to use media, such as plates, bottles, bags, and media in tubes; dehydrated media; agars and peptones; and supplements. The company also provides molecular biology and cell culture products which includes real time PCR, nucleic acid… Read more
Biomaxima - Asset Resilience Ratio
Biomaxima (BMX) has an Asset Resilience Ratio of 0.01% as of June 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2009–2022)
This chart shows how Biomaxima's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Biomaxima's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | zł0.00 | 0% |
| Short-term Investments | zł5.00K | 0.01% |
| Total Liquid Assets | zł5.00K | 0.01% |
Asset Resilience Insights
- Limited Liquidity: Biomaxima maintains only 0.01% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Biomaxima Industry Peers by Asset Resilience Ratio
Compare Biomaxima's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF |
Diagnostics & Research | 1.12% |
|
Berry Genomics Co Ltd
SHE:000710 |
Diagnostics & Research | 0.45% |
|
NSN Co. Ltd
KQ:031860 |
Diagnostics & Research | 1.72% |
|
JOONGANG DNM Co.Ltd
KQ:051980 |
Diagnostics & Research | 27.26% |
|
GeneMatrix Inc
KQ:109820 |
Diagnostics & Research | 41.52% |
|
Genoray Co. Ltd
KQ:122310 |
Diagnostics & Research | 0.03% |
|
Green Cross Lab Cell Corporation
KQ:144510 |
Diagnostics & Research | 0.18% |
|
Optipharm.CO.LTD
KQ:153710 |
Diagnostics & Research | 20.73% |
Annual Asset Resilience Ratio for Biomaxima (2009–2022)
The table below shows the annual Asset Resilience Ratio data for Biomaxima.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | 0.02% | zł13.00K | zł74.42 Million | 0.00pp |
| 2021-12-31 | 0.02% | zł13.00K | zł61.93 Million | 0.00pp |
| 2020-12-31 | 0.02% | zł13.00K | zł53.43 Million | 0.00pp |
| 2019-12-31 | 0.03% | zł12.44K | zł43.30 Million | +0.00pp |
| 2018-12-31 | 0.02% | zł10.94K | zł43.96 Million | -0.15pp |
| 2017-12-31 | 0.18% | zł48.00K | zł27.30 Million | -0.16pp |
| 2016-12-31 | 0.34% | zł78.71K | zł23.42 Million | -0.88pp |
| 2015-12-31 | 1.22% | zł267.04K | zł21.96 Million | -0.10pp |
| 2014-12-31 | 1.31% | zł281.04K | zł21.42 Million | -0.14pp |
| 2013-12-31 | 1.45% | zł327.06K | zł22.60 Million | -0.11pp |
| 2012-12-31 | 1.55% | zł302.78K | zł19.47 Million | -0.58pp |
| 2011-12-31 | 2.14% | zł280.71K | zł13.12 Million | +0.23pp |
| 2010-12-31 | 1.91% | zł200.64K | zł10.50 Million | -1.27pp |
| 2009-12-31 | 3.18% | zł182.40K | zł5.74 Million | -- |